The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma
NCT ID: NCT05088811
Last Updated: 2021-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2021-08-21
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A prospective case control study will be conducted on 80 subjects divided into three groups:
Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination.
Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
Patients will be recruited from the outpatient clinics and inpatient wards of Alexandria Main University Hospital and Medical Research Institute Hospital. Full informed consent will be taken from the patients and approval of the ethical committee of the Faculty of Medicine will be fulfilled. Exclusion criteria: Patients with any inflammatory diseases or other malignancies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver cirrhosis
Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
WRAP53, UCA-1
Diagnostic value of UCA-1 and WRAP53 in HCC
Hepatocellular Carcinoma
Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination
WRAP53, UCA-1
Diagnostic value of UCA-1 and WRAP53 in HCC
Control
Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
WRAP53, UCA-1
Diagnostic value of UCA-1 and WRAP53 in HCC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WRAP53, UCA-1
Diagnostic value of UCA-1 and WRAP53 in HCC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elsheaita, Ahmed Mohamed Elmoughazy Abdelfatah Aly
Assistant lecturer, experimental and clinical internal medicine, medical research institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria University, faculty of medicine
Alexandria, , Egypt
Alexandria University, medical research institute
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res. 2016 Feb;168:134-145. doi: 10.1016/j.trsl.2015.10.002. Epub 2015 Oct 24.
Pouladi N, Abdolahi S, Farajzadeh D, Hosseinpour Feizi MA. Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer. PLoS One. 2019 Aug 6;14(8):e0220727. doi: 10.1371/journal.pone.0220727. eCollection 2019.
Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015 Apr 10;6(10):7899-917. doi: 10.18632/oncotarget.3219.
Abdelmoety AA, Elhassafy MY, Said RSO, Elsheaita A, Mahmoud MM. The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study. Clin Exp Hepatol. 2023 Jun;9(2):129-137. doi: 10.5114/ceh.2023.127569. Epub 2023 Jun 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCC medical research institute
Identifier Type: -
Identifier Source: org_study_id